These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35241123)

  • 1. Advances in the diagnosis and treatment of sickle cell disease.
    Brandow AM; Liem RI
    J Hematol Oncol; 2022 Mar; 15(1):20. PubMed ID: 35241123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
    Talano JA; Cairo MS
    Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease.
    Bhatt S; Argueta DA; Gupta K; Kundu S
    Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291
    [No Abstract]   [Full Text] [Related]  

  • 5. An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
    Jeon WJ; Joung B; Moon JH; Hino C; Park D; Pham B; Castillo DR; Chong E; Kaur S; Grismore C; Cao H
    Hematology; 2023 Dec; 28(1):2215575. PubMed ID: 37227254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies.
    Malhotra M; Shenoy S
    Transfus Apher Sci; 2022 Oct; 61(5):103554. PubMed ID: 36096996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curative Therapies for Sickle Cell Disease.
    Kaviany S; Barnawi Z; LaBelle J
    Pediatr Ann; 2024 Feb; 53(2):e56-e61. PubMed ID: 38302122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sickle cell disease; a general overview.
    Schnog JB; Duits AJ; Muskiet FA; ten Cate H; Rojer RA; Brandjes DP
    Neth J Med; 2004 Nov; 62(10):364-74. PubMed ID: 15683091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?
    Tanhehco YC; Bhatia M
    Curr Opin Hematol; 2019 Nov; 26(6):448-452. PubMed ID: 31483336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review.
    Patel ZV; Prajjwal P; Bethineedi LD; Patel DJ; Khullar K; Patel H; Khatri K; Marsool MDM; Gadam S; Aleti S; Amir O
    J Blood Med; 2024; 15():435-447. PubMed ID: 39286637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
    Inusa BPD; Mnika K; Babiker S
    Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of curative therapies for sickle cell disease.
    Tanhehco YC; Nathu G; Vasovic LV
    Front Med (Lausanne); 2022; 9():1055540. PubMed ID: 36507504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
    Galacteros F; Ethgen O; Beillat M
    PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.